Q2 2026 13F · SEC CIK 1910264
SR One Capital Management, LP
Hedge fundFiled 2026-08-12 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $1.0B
- Reported positions
- 15
- Top holdings a year, 3 yrs
- +36.5%
- Assets under management
- $2.4B
SR One Capital Management, LP is a hedge fund that reported 15 positions worth $1.0B in its Q2 2026 13F, filed 2026-08-12. Its largest holdings were Veradermics Inc (MANE, 28.4%), Zenas Biopharma Inc (ZBIO, 12.3%), CRISPR Therapeutics AG (CRSP, 10.7%). A portfolio copying its top holdings returned 36.5% a year over the last 3 years, against 20.4% for the S&P 500.
SR One Capital Management, LP holdings all 15 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| MANEVeradermics Inc | 28.4% | +0.0% | $295.3M |
| ZBIOZenas Biopharma Inc | 12.3% | +0.0% | $127.9M |
| CRSPCRISPR Therapeutics AG | 10.7% | +0.0% | $111.2M |
| AVLNAvalyn Pharmaceuticals Inc | 10.5% | — | $108.9M |
| DSGNDesign Therapeutics, Inc. | 9.1% | +0.0% | $94.4M |
| ODTXOdyssey Therapeutics, Inc. | 6.8% | — | $71.0M |
| ALMSAlumis Inc Com | 5.3% | +0.0% | $55.2M |
| ORICOric Pharmaceuticals Inc | 4.8% | +2.2% | $50.0M |
| MLYSMineralys Therapeutics Inc | 4.1% | +0.0% | $42.2M |
| SPRYArs Pharmaceuticals Inc | 3.1% | +0.0% | $32.1M |
| MOBIMobia Medical, Inc | 2.6% | — | $26.6M |
| NKTXNkarta Inc | 0.9% | +0.0% | $9.4M |
| OCSOculis Holding AG | 0.9% | +0.0% | $8.9M |
| RAREUltragenyx Pharmaceutical in | 0.4% | +0.0% | $4.6M |
| ENGNenGene Holdings Inc. | 0.1% | +0.0% | $1.3M |
What SR One Capital Management, LP bought and sold in Q2 2026, against Q1 2026.
New positions
- AVLN Avalyn Pharmaceuticals Inc10.5% of 13F
- ODTX Odyssey Therapeutics, Inc.6.8% of 13F
- MOBI Mobia Medical, Inc2.6% of 13F
Added to
No position grew by more than 5%.
Reduced
No position shrank by more than 5%.
Sold out
- ACLX Arcellx Incwas 29.4%
- ORKA Oruka Therapeutics Incwas 2.3%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +51.6% /yr
- S&P 500 +20.1%
- 3 years
- +36.5% /yr
- S&P 500 +20.4%
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $1.0B | 15 |
| Q1 2026 | $915.4M | 14 |
| Q4 2025 | $706.4M | 13 |
| Q3 2025 | $691.4M | 12 |
| Q2 2025 | $461.4M | 13 |
| Q1 2025 | $389.3M | 12 |
| Q4 2024 | $410.1M | 11 |
| Q3 2024 | $498.7M | 11 |
| Q2 2024 | $319.4M | 9 |
| Q1 2024 | $364.1M | 6 |
| Q4 2023 | $238.2M | 5 |
| Q3 2023 | $195.1M | 6 |
Questions about SR One Capital Management, LP's portfolio
What stocks does SR One Capital Management, LP own?
SR One Capital Management, LP's latest 13F, for Q2 2026 and filed Aug 12, 2026, lists 15 positions worth $1.0B. The largest are Veradermics Inc (MANE) at 28.4%, Zenas Biopharma Inc (ZBIO) at 12.3%, CRISPR Therapeutics AG (CRSP) at 10.7%, Avalyn Pharmaceuticals Inc (AVLN) at 10.5% and Design Therapeutics, Inc. (DSGN) at 9.1%.
What did SR One Capital Management, LP buy last quarter?
In Q2 2026, SR One Capital Management, LP added a new position in Avalyn Pharmaceuticals Inc (AVLN), a new position in Odyssey Therapeutics, Inc. (ODTX) and a new position in Mobia Medical, Inc (MOBI), compared with its Q1 2026 filing.
What did SR One Capital Management, LP sell last quarter?
In Q2 2026, SR One Capital Management, LP sold all of Arcellx Inc (ACLX) and sold all of Oruka Therapeutics Inc (ORKA), compared with its Q1 2026 filing.
How has SR One Capital Management, LP's portfolio performed?
A portfolio copying SR One Capital Management, LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +36.5% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +51.6% against +20.1%.
When is SR One Capital Management, LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. SR One Capital Management, LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does SR One Capital Management, LP manage?
SR One Capital Management, LP reported $2.4B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $1.0B.